Charles River Laboratories
583 hedge funds and large institutions have $9.9B invested in Charles River Laboratories in 2022 Q3 according to their latest regulatory filings, with 64 funds opening new positions, 229 increasing their positions, 210 reducing their positions, and 98 closing their positions.
154% more call options, than puts
Call options by funds: $33.9M | Put options by funds: $13.3M
150% more funds holding in top 10
Funds holding in top 10: 4 → 10 (+6)
3.08% more ownership
Funds ownership: 95.87% → 98.95% (+3.1%)
9% more repeat investments, than reductions
Existing positions increased: 229 | Existing positions reduced: 210
5% less capital invested
Capital invested by funds: $10.4B → $9.9B (-$517M)
7% less funds holding
Funds holding: 627 → 583 (-44)
35% less first-time investments, than exits
New positions opened: 64 | Existing positions closed: 98
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$108M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$104M |
| 3 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$94M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$71.5M |
| 5 |
EARNEST Partners
Atlanta,
Georgia
|
+$62.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$169M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$127M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$126M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
-$59.9M |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$59.7M |
CRL Hedge Fund Activity: Q3 2022 in Review
583 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q3 2022, worth a combined $9.9B — down 5% from $10.4B a quarter earlier.
Sellers outnumbered buyers: 98 funds closed out of CRL and 64 opened new positions — a net loss of 34 holders — while 210 trimmed existing stakes and 229 added.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $108M. The largest seller was Fidelity Investments, cutting an estimated $169M.
- 583 institutional investors held Charles River Laboratories (CRL) as of Q3 2022, down from 627 in Q2 2022.
- Funds reported $9.9B of Charles River Laboratories stock for Q3 2022, down 5% quarter-over-quarter.
- 64 funds opened new Charles River Laboratories positions in Q3 2022 and 98 closed out, a net change of -34 holders.
- The largest Charles River Laboratories buyer in Q3 2022 was Camber Capital Management, an estimated $108M added.
- The largest Charles River Laboratories seller in Q3 2022 was Fidelity Investments, an estimated $169M sold.
Based on aggregated 13F filings for Q3 2022.